Jaktinib is an orally active small-molecule Janus kinase (JAK) inhibitor developed for the treatment of myelofibrosis and other diseases associated with abnormal JAK-mediated signaling. It inhibits JAK family signaling involved in cytokine-mediated inflammation, hematopoiesis and proliferation of abnormal blood cells.
Jaktinib is particularly associated with inhibition of JAK1 and JAK2, including activity against signaling pathways involving the JAK2 V617F mutation. By reducing abnormal JAK-STAT signaling, Jaktinib can help suppress disease-associated cytokine signaling and abnormal myeloid-cell proliferation.
Jaktinib is a synthetic small-molecule kinase inhibitor. It is also known by the development code INCB052793 in some research references. The compound is supplied for pharmaceutical development and manufacturing applications according to the applicable specification.
Jaktinib inhibits Janus kinase signaling, particularly JAK1 and JAK2. JAK proteins transmit signals from cytokine receptors to STAT transcription factors. Inhibition of these pathways can reduce abnormal cytokine signaling and myeloproliferative activity associated with myelofibrosis.
Jaktinib has been developed primarily for the treatment of myelofibrosis, including intermediate- and high-risk disease. It has also been investigated for other hematological and inflammatory conditions involving JAK-STAT signaling.
Jaktinib API can be evaluated using validated analytical procedures for identity, assay, related substances, residual solvents, water content and elemental impurities. HPLC and suitable spectroscopic techniques may be used for identity and purity assessment.
Acceptance criteria for assay, impurities and other quality attributes should be based on the applicable approved drug-substance specification and Certificate of Analysis.
Jaktinib should be stored in a tightly closed pharmaceutical-grade container under controlled storage conditions. The material should be protected from excessive heat, moisture, direct light and contamination. Specific storage requirements should follow the applicable manufacturer's specification.
Jaktinib API may be supplied for qualified pharmaceutical manufacturing, formulation development, research and analytical applications, subject to applicable regulatory requirements. Product specifications, Certificate of Analysis, packaging configuration and regulatory documentation should be confirmed according to the intended application.
Jaktinib API is available for pharmaceutical development and manufacturing requirements subject to applicable quality and regulatory requirements. Customers can request product specifications, analytical documentation, Certificate of Analysis, packaging information and commercial details for their specific requirements.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| pH (1% Solution) | 5.0 – 7.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |